Literature DB >> 31380987

Association of Levels of Specialized Care With Risk of Premature Mortality in Patients With Epilepsy.

Mark W Lowerison1, Colin B Josephson1,2,3, Nathalie Jetté1,2,4, Tolulope T Sajobi1,3, Scott Patten1,3, Tyler Williamson1, Rob Deardon1,5,6, Herman W Barkema1,5, Samuel Wiebe1,2,3.   

Abstract

Importance: Patients with epilepsy are at an elevated risk of premature mortality. Interventions to reduce this risk are crucial. Objective: To determine if the level of care (non-neurologist, neurologist, or comprehensive epilepsy program) is negatively associated with the risk of premature mortality. Design, Setting, and Participants: In this retrospective open cohort study, all adult patients 18 years or older who met the administrative case definition for incident epilepsy in linked databases (Alberta Health Services administrative health data and the Comprehensive Calgary Epilepsy Programme Registry [CEP]) inclusive of the years 2002 to 2016 were followed up until death or loss to follow-up. The final analyses were performed on May 1, 2019. Exposures: Evaluation by a non-neurologist, neurologist, or epileptologist. Main Outcomes and Measures: The outcome was all-cause mortality. We used extended Cox models treating exposure to a neurologist or the CEP as time-varying covariates. Age, sex, socioeconomic deprivation, disease severity, and comorbid burden at index date were modeled as fixed-time coefficients.
Results: A total 23 653 incident cases were identified (annual incidence of 89 per 100 000); the mean age (SD) at index date was 50.8 (19.1) years and 12 158 (50.3%) were women. A total of 14 099 (60%) were not exposed to specialist neurological care, 9554 (40%) received care by a neurologist, and 2054 (9%) received care in the CEP. In total, 4098 deaths (71%) occurred in the nonspecialist setting, 1481 (26%) for those seen by a neurologist, and 176 (3%) for those receiving CEP care. The standardized mortality rate was 7.2% for the entire cohort, 9.4% for those receiving nonspecialist care, 5.6% for those seen by a neurologist, and 2.8% for those seen in the CEP. The hazard ratio (HR) of mortality was lower in those receiving neurologist (HR, 0.85; 95% CI, 0.77-0.93) and CEP (HR, 0.49; 95% CI, 0.38-0.62) care. In multivariable modeling, specialist care, the age at index, and disease severity were retained in the final model of the association between specialist care and mortality. Conclusions and Relevance: Exposure to specialist care is associated with incremental reductions in the hazard of premature mortality. Those referred to a comprehensive epilepsy program received the greatest benefit.

Entities:  

Mesh:

Year:  2019        PMID: 31380987      PMCID: PMC6686748          DOI: 10.1001/jamaneurol.2019.2268

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  29 in total

Review 1.  The role of patient care teams in chronic disease management.

Authors:  E H Wagner
Journal:  BMJ       Date:  2000-02-26

2.  Development of an epilepsy-specific risk adjustment comorbidity index.

Authors:  Christine St Germaine-Smith; MingFu Liu; Hude Quan; Samuel Wiebe; Nathalie Jette
Journal:  Epilepsia       Date:  2011-10-17       Impact factor: 5.864

Review 3.  Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies.

Authors:  Kirsten M Fiest; Khara M Sauro; Samuel Wiebe; Scott B Patten; Churl-Su Kwon; Jonathan Dykeman; Tamara Pringsheim; Diane L Lorenzetti; Nathalie Jetté
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

4.  Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.

Authors:  M J Brodie; J P Mumford
Journal:  Epilepsy Res       Date:  1999-04       Impact factor: 3.045

5.  A randomized, controlled trial of surgery for temporal-lobe epilepsy.

Authors:  S Wiebe; W T Blume; J P Girvin; M Eliasziw
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

Review 6.  Treating the right patient at the right time: access to specialist consultation and non-invasive testing.

Authors:  Merril L Knudtson; Rob Beanlands; James M Brophy; Lyall Higginson; Brad Munt; John Rottger
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

7.  The risks of waiting for cardiac catheterization: a prospective study.

Authors:  Madhu K Natarajan; Shamir R Mehta; Douglas H Holder; David R Goodhart; Amiram Gafni; Donald Shilton; Rizwan Afzal; Koon Teo; Salim Yusuf
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

8.  How common are the "common" neurologic disorders?

Authors:  D Hirtz; D J Thurman; K Gwinn-Hardy; M Mohamed; A R Chaudhuri; R Zalutsky
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

9.  Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.

Authors:  M J Brodie; A W Yuen
Journal:  Epilepsy Res       Date:  1997-03       Impact factor: 3.045

10.  Mindfulness-based therapy for drug-resistant epilepsy: An assessor-blinded randomized trial.

Authors:  Venus Tang; Wai S Poon; Patrick Kwan
Journal:  Neurology       Date:  2015-09-02       Impact factor: 9.910

View more
  7 in total

1.  Error in Labels for Number at Risk.

Authors: 
Journal:  JAMA Neurol       Date:  2020-05-01       Impact factor: 18.302

Review 2.  Autonomic manifestations of epilepsy: emerging pathways to sudden death?

Authors:  Roland D Thijs; Philippe Ryvlin; Rainer Surges
Journal:  Nat Rev Neurol       Date:  2021-10-29       Impact factor: 42.937

3.  Timing of referral to evaluate for epilepsy surgery: Expert Consensus Recommendations from the Surgical Therapies Commission of the International League Against Epilepsy.

Authors:  Lara Jehi; Nathalie Jette; Churl-Su Kwon; Colin B Josephson; Jorge G Burneo; Fernando Cendes; Michael R Sperling; Sallie Baxendale; Robyn M Busch; Chahnez Charfi Triki; J Helen Cross; Dana Ekstein; Dario J Englot; Guoming Luan; Andre Palmini; Loreto Rios; Xiongfei Wang; Karl Roessler; Bertil Rydenhag; Georgia Ramantani; Stephan Schuele; Jo M Wilmshurst; Sarah Wilson; Samuel Wiebe
Journal:  Epilepsia       Date:  2022-07-17       Impact factor: 6.740

4.  Factors Predicting Outcome After Intracranial EEG Evaluation in Patients With Medically Refractory Epilepsy.

Authors:  Adithya Sivaraju; Lawrence Hirsch; Nicolas Gaspard; Pue Farooque; Jason Gerrard; Yunshan Xu; Yanhong Deng; Eyiyemisi Damisah; Hal Blumenfeld; Dennis D Spencer
Journal:  Neurology       Date:  2022-05-04       Impact factor: 11.800

5.  Equity and the JAMA Network.

Authors:  Phil B Fontanarosa; Annette Flanagin; John Z Ayanian; Robert O Bonow; Neil M Bressler; Dimitri Christakis; Mary L Disis; S Andrew Josephson; Melina R Kibbe; Dost Öngür; Jay F Piccirillo; Rita F Redberg; Frederick P Rivara; Kanade Shinkai; Clyde W Yancy
Journal:  JAMA Neurol       Date:  2021-08-01       Impact factor: 29.907

6.  Importance of access to epilepsy monitoring units during the COVID-19 pandemic: Consensus statement of the International League against epilepsy and the International Federation of Clinical Neurophysiology.

Authors:  Sándor Beniczky; Aatif Husain; Akio Ikeda; Haifa Alabri; J Helen Cross; Jo Wilmshurst; Margitta Seeck; Niels Focke; Patricia Braga; Samuel Wiebe; Stephan Schuele; Eugen Trinka
Journal:  Clin Neurophysiol       Date:  2021-07-15       Impact factor: 3.708

7.  Pharmacologic treatment and SUDEP risk: A nationwide, population-based, case-control study.

Authors:  Olafur Sveinsson; Tomas Andersson; Peter Mattsson; Sofia Carlsson; Torbjörn Tomson
Journal:  Neurology       Date:  2020-09-23       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.